156 related articles for article (PubMed ID: 18046889)
41. New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach.
Juergens LJ; Worth H; Juergens UR
Adv Ther; 2020 May; 37(5):1737-1753. PubMed ID: 32200535
[TBL] [Abstract][Full Text] [Related]
42. Mucoactive drugs for asthma and COPD: any place in therapy?
Rogers DF
Expert Opin Investig Drugs; 2002 Jan; 11(1):15-35. PubMed ID: 11772318
[TBL] [Abstract][Full Text] [Related]
43. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD.
Short PM; Williamson PA; Elder DHJ; Lipworth SIW; Schembri S; Lipworth BJ
Chest; 2012 Jan; 141(1):81-86. PubMed ID: 21799028
[TBL] [Abstract][Full Text] [Related]
44. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
Hanania NA
Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
[TBL] [Abstract][Full Text] [Related]
45. Erdosteine: its relevance in COPD treatment.
Moretti M
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):333-43. PubMed ID: 19331595
[TBL] [Abstract][Full Text] [Related]
46. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
Niewoehner DE; Rice K; Cote C; Paulson D; Cooper JA; Korducki L; Cassino C; Kesten S
Ann Intern Med; 2005 Sep; 143(5):317-26. PubMed ID: 16144890
[TBL] [Abstract][Full Text] [Related]
47. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
Sobieraj DM; White CM; Coleman CI
Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
[TBL] [Abstract][Full Text] [Related]
48. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice.
Kaplan AG
Int J Chron Obstruct Pulmon Dis; 2015; 10():2535-48. PubMed ID: 26648711
[TBL] [Abstract][Full Text] [Related]
49. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
JAMA; 2018 Oct; 320(15):1548-1559. PubMed ID: 30326124
[TBL] [Abstract][Full Text] [Related]
50. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
51. Antioxidants and mucolytics in COPD management: when (if ever) and in whom?
Hillas G; Nikolakopoulou S; Hussain S; Vassilakopoulos T
Curr Drug Targets; 2013 Feb; 14(2):225-34. PubMed ID: 23256719
[TBL] [Abstract][Full Text] [Related]
52. Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease?
Burge S
Drugs; 2001; 61(11):1535-44. PubMed ID: 11577791
[TBL] [Abstract][Full Text] [Related]
53. Clinical Pharmacology of Oral Maintenance Therapies for Obstructive Lung Diseases.
Pleasants RA
Respir Care; 2018 Jun; 63(6):671-689. PubMed ID: 29794203
[TBL] [Abstract][Full Text] [Related]
54. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
[TBL] [Abstract][Full Text] [Related]
55. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
[TBL] [Abstract][Full Text] [Related]
56. Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study.
Morjaria JB; Rigby A; Morice AH
Lung; 2017 Jun; 195(3):281-288. PubMed ID: 28255905
[TBL] [Abstract][Full Text] [Related]
57. Mucoactive therapy in COPD.
Decramer M; Janssens W
Eur Respir Rev; 2010 Jun; 19(116):134-40. PubMed ID: 20956182
[TBL] [Abstract][Full Text] [Related]
58. Inhaled corticosteroids in chronic obstructive pulmonary disease: a review.
Telenga ED; Kerstjens HA; Postma DS; Ten Hacken NH; van den Berge M
Expert Opin Pharmacother; 2010 Feb; 11(3):405-21. PubMed ID: 20102305
[TBL] [Abstract][Full Text] [Related]
59. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM
Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
[TBL] [Abstract][Full Text] [Related]
60. Prediction and prevention of exacerbations and mortality in patients with COPD.
Kostikas K; Clemens A; Patalano F
Expert Rev Respir Med; 2016 Jul; 10(7):739-53. PubMed ID: 27135786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
